Product Description
Overall, the global dental bone graft substitute and other biomaterials market was valued at $2.33 billion in 2025. This is expected to increase over the forecast period at a CAGR of 7.2% to reach nearly $3.8 billion.
The full report suite on the global market for dental bone graft substitutes and other biomaterials includes dental bone graft substitutes, dental barrier membranes, local antimicrobial periodontal treatments and dental wound care. Collectively, these segments will be referred to as the dental biomaterials market.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Global Dental Bone Graft Substitute and Other Biomaterials Market Trends

Growth in the dental bone graft substitute market remains closely tied to developments in the dental implant market, as a substantial proportion of implant procedures continue to require bone grafting to address insufficient bone volume or quality at the implant site. As global adoption of dental implants increases, driven by aging populations, higher rates of tooth loss, expanding access to care and growing patient preference for implant-based restorations, demand for dental bone graft substitutes is expected to rise accordingly. At the same time, improvements in dental infrastructure, practitioner training and overall access to dental care are enabling a greater share of clinically eligible patients to receive implant and grafting procedures, supporting near- to mid-term market growth. While long-term improvements in preventive oral healthcare may reduce the incidence of severe tooth loss in certain populations, demographic trends, longer life expectancy and increasing expectations for functional and aesthetic dental outcomes are expected to sustain steady demand for bone graft substitutes over the forecast period.
Global Dental Bone Graft Substitute and Other Biomaterials Market Share Insights

- Geistlich Pharma remains a leading competitor in the global dental bone graft substitute (DBGS) and dental biomaterials market, holding significant shares in both the DBGS and dental barrier membrane segments. The company’s focus on bone and soft-tissue regeneration has provided it with a strong position in the regenerative dentistry market. Its Bio-Oss® bovine xenograft and Bio-Gide® collagen membrane product lines are widely used in guided bone regeneration procedures. Geistlich has also strengthened its market position through recent strategic developments, including the 2024 acquisition of Bionnovation Biomedical, a 2025 investment in ReOss focused on patient-specific regenerative solutions and continued expansion of its regenerative portfolio with new membrane technologies expected to be introduced around 2026. Despite increasing competition from lower-priced xenograft and collagen membrane products offered by regional manufacturers, Geistlich is expected to maintain a strong presence in the dental biomaterials market over the forecast period.
- Henry Schein has strengthened its position as the second-largest global competitor in the dental bone graft substitutes market in 2025, driven primarily by the performance of its specialty brands, most notably BioHorizons and ACE Southern. BioHorizons continues to serve as the cornerstone of Henry Schein’s regenerative and implant-related portfolio, offering a comprehensive range of DBGS products, including MinerOss®, Grafton® DBM and LADDEC®, which support a broad spectrum of grafting indications. The MinerOss® platform includes cortical, cancellous and composite allograft options, enabling BioHorizons to address both routine and complex clinical cases. While BioHorizons is often categorized as a mid-sized competitor relative to the largest pure-play biomaterials manufacturers, its consistent expansion across dental implant and regenerative product segments has significantly amplified Henry Schein’s global footprint. In parallel, ACE Southern has enhanced Henry Schein’s reach through its strong presence in surgical and grafting consumables, reinforcing distribution depth and brand visibility. Collectively, the performance of these subsidiary brands has been central to Henry Schein’s competitive positioning and sustained growth in the global dental bone graft substitutes market.
- ZimVie remained a leading competitor in the global dental bone graft substitute (DBGS) and dental biomaterials market in 2025. The company maintains its competitive position through a broad regenerative biomaterials portfolio spanning key segments such as allografts, xenografts, synthetic grafts and barrier membranes. ZimVie’s Puros® Allograft, along with its RegenerOss® and Endobon® product lines, competes with offerings from major biomaterials manufacturers, including Geistlich Pharma and BioHorizons. In 2025, ZimVie was acquired by the private equity firm ARCHIMED, transitioning the company from a publicly traded entity to a privately held company. This acquisition is expected to support further investment in ZimVie’s dental implant and regenerative biomaterials portfolio, strengthening its position in the global dental biomaterials market over the forecast period.
Global Dental Bone Graft Substitute and Other Biomaterials Market Segmentation Summary
- Dental Bone Graft Substitute Market – Further Segmented Into:
- Type: Allograft, Xenograft, and Synthetic.
- Application*: Socket Preservation, Sinus Augmentation, Ridge Augmentation, Periodontal Procedure.
- Dental Barrier Membrane Market – Further Segmented Into:
- Type: Resorbable, and Non-Resorbable.
- Material: Xenografts, Synthetics, and Allografts.
- Local Antimicrobial Periodontal Treatment Market
- Dental Soft Tissue Wound Care Market – Further Segmented Into:
- Type: Plug, Tape, and Foam.
*Segment is analyzed at a unit level only.
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Region | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.